Company Description
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.
RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.
The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Jul 30, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 498 |
| CEO | Ronald Kurtz |
Contact Details
Address: 100 Columbia Aliso Viejo, California 92656 United States | |
| Phone | 949 521 7830 |
| Website | rxsight.com |
Stock Details
| Ticker Symbol | RXST |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001111485 |
| CUSIP Number | 78349D107 |
| ISIN Number | US78349D1072 |
| Employer ID | 94-3268801 |
| SIC Code | 3851 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ronald M. Kurtz M.D. | President, Chief Executive Officer and Director |
| Dr. Ilya Goldshleger Ph.D. | Chief Operating Officer |
| Eric J. Weinberg | Chief Business Development Officer |
| Mark Wilterding | Chief Financial Officer |
| Oliver Moravcevic | Vice President of Investor Relations |
| Jim Schindler | Senior Vice President and General Counsel |
| Scott Gaines | Chief Customer Officer |
| Maureen O'Connell | Executive Vice President of Clinical and Regulatory Affairs |
| Patrick Cullen | Executive Vice President of Quality and Infrastructure Operations |
| Adam Dashe | Executive Vice President of International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | EFFECT | Notice of Effectiveness |
| Feb 25, 2026 | POS AM | Post-Effective amendments for registration statement |
| Feb 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 13, 2026 | POSASR | Filing |
| Feb 3, 2026 | SCHEDULE 13G | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 23, 2025 | 8-K | Current Report |
| Dec 22, 2025 | 8-K | Current Report |